Alliance Pharma acquires US scar treatment brand

Scaraway

Chippenham-based healthcare group Alliance Pharma has completed its acquisition of silicone-based scar treatment brand ScarAway in the US.

Alliance bought ScarAway, as well as the rights to sell Kelo-cote, from Perrigo Company PLC for £14.8 million ($19.4 million).

ScarAway is the leading silicone-based scar treatment, and the second-largest scar treatment brand, in the US with net 12-month sales of around $10 million and market share of 28 per cent.

The US is the second-largest global market for scar treatments with an estimated current retail value of around $90 million per annum.

Alliance said the acquisition accelerates its strategy in the US, providing another strong consumer brand with an established distribution platform from which to drive further growth.

Alliance CEO Peter Butterfield said: “I’m delighted to have completed such a strategically important and earnings enhancing acquisition for Alliance which creates our first fully global brand in Kelo-cote and significantly enhances our presence in the largest consumer healthcare market in the world.”